- Home
- NVCT vs CIK Comparison
NVCT vs CIK Comparison
Compare NVCT & CIK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NVCT | CIK |
|---|---|---|
| Founded | 2020 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 193.4M | 156.2M |
| IPO Year | 2022 | N/A |
Fundamental Metrics
Financial Performance| Metric | NVCT | CIK |
|---|---|---|
| Price | $8.68 | $2.85 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $15.33 | N/A |
| AVG Volume (30 Days) | 70.7K | ★ 115.4K |
| Earning Date | 02-24-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 9.03% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.55 | $2.50 |
| 52 Week High | $11.52 | $3.19 |
Technical Indicators
Market Signals| Indicator | NVCT | CIK |
|---|---|---|
| Relative Strength Index (RSI) | 57.10 | 52.31 |
| Support Level | $8.08 | $2.84 |
| Resistance Level | $8.93 | $2.88 |
| Average True Range (ATR) | 0.51 | 0.02 |
| MACD | -0.04 | -0.00 |
| Stochastic Oscillator | 37.79 | 44.44 |
Price Performance
Historical ComparisonAbout NVCT Nuvectis Pharma Inc.
Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of innovative precision medicines for the treatment of serious conditions of unmet medical needs in oncology. It operates with one segment, focused on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its pipeline products include NXP800, NXP900.
About CIK Credit Suisse Asset Management Income Fund Inc.
Credit Suisse Asset Mgmt Income Fund Inc is a closed-end management investment company. The investment objective of the fund is to provide current income consistent with the preservation of capital. Credit Suisse serves as an investment adviser for the fund. Asset Management offers a wide range of investment products and functions across asset classes and investment styles. The division manages various regional portfolios, mutual funds, and other investment vehicles for governments, institutions, corporations and individuals.